Jade Biosciences (NASDAQ:JBIO) said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company’s plan to advance the antibody into patient studies for IgA nephropathy.
Chief Executive Officer Tom Frohlich said JADE101, a fully human monoclonal antibody designed to selectively inhibit APRIL, “exceeded our expectations” in the Phase 1 trial. APRIL is described by the company as a key driver of pathogenic IgA production in IgA nephropathy, a progressive autoimmune kidney disease that can lead to kidney failure.
